atomoxetine hydrochloride has been researched along with Intellectual Disability in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, J; Perera, B; Shankar, R | 1 |
| Biederman, J; Firmin, ES; Hoskova, B; Joshi, G; Wilens, T | 1 |
| Cheng, AT; Chou, WJ; Tang, CS | 1 |
| Findling, RL; Rowles, BM | 1 |
| Brown, TE; Evans, SW; Gotlieb, EM; Knight, JR; Ross, EC; Shubiner, HH; Wender, EH; Wibbelsman, CJ; Wilens, T; Wolraich, ML | 1 |
| McCarthy, J | 1 |
5 review(s) available for atomoxetine hydrochloride and Intellectual Disability
| Article | Year |
|---|---|
Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Cognition; Dextroamphetamine; Humans; Intellectual Disability; Methylphenidate; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Guanfacine; Humans; Intellectual Disability; Methylphenidate; Treatment Outcome | 2021 |
Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders.
Topics: Adolescent; Amphetamines; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Child, Preschool; Clinical Trials as Topic; Clonidine; Comorbidity; Developmental Disabilities; Drug Therapy, Combination; Female; Fetal Alcohol Spectrum Disorders; Humans; Intellectual Disability; Male; Methylphenidate; Pregnancy; Propylamines; Psychotropic Drugs | 2010 |
Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications.
Topics: Adolescent; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Case Management; Central Nervous System Stimulants; Child; Clonidine; Comorbidity; Continuity of Patient Care; Family Health; Female; Forecasting; Health Services Accessibility; Humans; Insurance Coverage; Intellectual Disability; Male; Mental Disorders; Patient Compliance; Propylamines; Puberty; Risk; Substance-Related Disorders | 2005 |
Children with autism spectrum disorders and intellectual disability.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; Child; Humans; Intellectual Disability; Methylphenidate; Prevalence; Propylamines | 2007 |
1 other study(ies) available for atomoxetine hydrochloride and Intellectual Disability
| Article | Year |
|---|---|
Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Intellectual Disability; Male; Propylamines; Psychoses, Substance-Induced | 2009 |